Best-Selling Diabetes Drug Dropped by CVS

By Natalie Moore Posted August 10, 2016

• Discover why CVS is making an unexpected and unconventional change to their formulary
• Find out how a new type of drug may slaughter Big Pharma’s cash cows
• Plus, the proven way to reverse diabetes naturally without expensive pills and painful injections.

Dear Reader,

“But I’ve been taking this for years! Why can’t I still get it? And what is this replacement? A bio-what?!”

If you have diabetes, this could be what you’re saying at the pharmacy in the coming year.

Last week, CVS announced it will drop the insulin drug Lantus from its list of insurance-reimbursed medications — making this the biggest commercial product ever cut from a formulary.

This means if you’re one of the hundreds of thousands of people taking Lantus and getting your prescriptions from CVS, you’ll either be forced to take a new drug, find a new pharmacy or perhaps pay full price.

While this change seems a bit unconventional considering that Lantus is one of the best-selling drugs of all time, CVS has a reason for making the switch — money.

And it might be your reason for switching as well.

Making the Switch

CVS, the largest chain of drug stores in the U.S., has chosen to replace Lantus with Eli Lilly’s biosimilar Basaglar.

Lantus, whose patent expired last year, is a high-priced type of drug called a biologic. Biologic drugs are made from living organisms, rather than the chemical compounds found in traditional drugs. But since its patent is up, it can be replaced with a biosimilar drug.

Basaglar and other biosimilar drugs are cheaper copies of protein-based biologics. In other words, biosimilars are the generic equivalent versions of high-priced, patent-protected biologics.

To be clear, biosimilars aren’t exact copies of biologic drugs. Yet biosimilar replacements have shown to be equivalent to patent-protected biologics in terms of efficacy and side effects.

The big appeal of biosimilar drugs for CVS and other pharmacies is cost. Biosimilars cost 15–30 percent less than their branded counterparts. Even though these discounts are a far cry from the 50–80 percent savings seen with traditional generics, it’s enough to get insurance providers’ attention. This switch will undoubtedly cut costs for insurers and perhaps customers.

CVS’s decision to adopt Basaglar came out as a new study from Johns Hopkins University and Brigham and Women’s Hospital found that biosimilars had similar treatment effects as biologics on rheumatoid arthritis and inflammatory bowel disease.

Biosimilar drugs have been used in Europe for decades with no reported health problems. While the U.S. has stricter reporting and approval processes for drugs than Europe, this is still a good indicator of the safety and efficacy of biosimilar drugs.

Troyen Brennan, CVS’s chief health officer and a physician, reports that this formulary change shouldn’t be controversial as the company has reviewed the drug’s efficacy with a panel of experts. Though, if a customer has a problem with taking a biosimilar, they should seek a “formulary exception.” If approved, the requested drug should be covered in full by CVS. If not, you may end up paying full price.

Even with this anecdotal evidence and the promise of reduced drug costs, there is one group that has an issue with biosimilar drugs…

You guessed it — Big Pharma.

Biosimilar Drugs Don’t Make Similar Profits

The introduction of biosimilar drugs to the market means less profits for some pharmaceutical companies.

Since CVS is the second-largest pharmacy benefit manager and the first to adopt a biosimilar drug over a biologic here in the U.S., there’s a good chance other groups will follow.

If this happens, it could threaten drugmakers’ biggest cash cows.

In fact, Express Scripts, the only pharmacy benefit manager larger than CVS, reports that if biosimilars are created for the 11 leading drugs in the U.S., it would save the country over $250 billion during the next decade.

The good news is, there’s a proven way to fight diabetes that doesn’t require a trip to the pharmacy and doesn’t cost you a dime. It’s all outlined in your free copy of Daniel’s Diabetic Miracle, which you received when you became a subscribe to Brad Lemley’s Natural Health Solutions.

Inside this report, you’ll discover the one simple way to rid yourself of the complications of diabetes and live a life free from the painful injections, expensive pills and irritating blood tests that so often come along with diabetes.

Here are some of the amazing health results Natural Health Solutions readers have experienced using Daniel’s Diabetic Miracle:

I’ve been following your dietary guidelines and have lost weight, lowered my blood sugar, And best of all, been able to get off my diabetic medicine! – Ruth R.

Over the last month, I have lost 26 pounds. I’m off all my diabetes medications. And my blood sugar appears to be well under control. -K.M.

If you’re not a subscriber to Brad Lemley’s Natural Health Solutions and would like to get access to this groundbreaking report, click here.

Live well,

Natalie Moore
Managing editor, Living Well Daily

Sources

^[1] Biologic drugmakers use patents, suits to thwart generic competition

^[2] CVS drops Sanofi’s diabetes drugs for biosimilars

^[3] Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review

^[4] ‘Audacious’ CVS formulary drops key meds from Sanofi, Medivation and Novartis. Yours could be next

^[5] ‘Biosimilar’ drugs could save patients, USA billions

^[6] FDA approves Adlyxin to treat type 2 diabetes

Written By Natalie Moore

Natalie Moore is a dedicated health researcher with a passion for finding healthy, natural, and science-based solutions. After a decade of direct healthcare experience in western and natural medicine, she was involved in public health research before joining Living Well Daily.

View More By Natalie Moore